Company intelligence / Profile preview

Senju Pharmaceutical Co., Ltd.

Ownership: Private
Development stage: Commercial

Overview

Senju Pharmaceutical has a long history of developing prescription and OTC drugs for ophthalmology. Recent clinical results include the launch of Mytear Lumify for dry-eye analysis software in Japan after regulatory approval in September/November 2024. The company continues to expand its product portfolio with both innovative prescription medicines and consumer health products targeting the five senses (eyes, ears, nose, throat, skin).

Therapeutic areas: ImmunologyOtherOphthalmologyInfectious Diseases
Modalities: Small moleculeBiologics
Industry: Biotech

Drug pipeline

12 assets

fonadelpar

11 more assets in the full pipeline.

Request access →

Partnerships

Takeda Pharmaceutical Company LimitedSemaThera Inc.

Beyond the preview

Go deeper on Senju Pharmaceutical Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Senju Pharmaceutical Co., Ltd..

Explore the full profile